Nevertheless, this original trial was also developed through small sample research (N = 28), single cancer type (NSCLC), and monotherapy (nivolumab, a PD-1 blocker), and the prognostic value of iPERCIST should be confirmed in large prospective multicentric studies. Here, PDCD1 is linked to cancer.